CTOs on the Move

EIP Pharma

www.eippharma.com

 
EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

EIP Pharma raised $20.5M on 05/16/2018

Similar Companies

ChristieCampusHealth

CONNECT@College from Christie Campus Health helps colleges provide behavioral and mental health support for students, and logistical support for campus healthcare providers.

Taro Pharmaceutical Industries

Taro Pharmaceutical Industries is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Maclean Health

Maclean Health is a medical and pharmaceutical products wholesale distributor that specializes in supplying market innovators to government and private healthcare partners.

Cannon Building Services Inc

Cannon Building Services Inc is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.